Overview

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

Status:
Completed
Trial end date:
2018-10-02
Target enrollment:
Participant gender:
Summary
This is a Phase I study to understand the biodistribution of MM-398 and to determine the feasibility of using Ferumoxytol as a tumor imaging agent.
Phase:
Phase 1
Details
Lead Sponsor:
Ipsen
Merrimack Pharmaceuticals
Treatments:
Camptothecin
Ferrosoferric Oxide